Stroke and bleeding risk evaluation in atrial fibrillation: results of the European Heart Rhythm Association survey

Torben Bjerregaard Larsen; Tatjana Potpara; Nikolaos Dagres; Laurent Pison; Heidi Estner; Carina Blomstrom-Lundqvist

doi:10.1093/europace/euu089

Stroke and bleeding risk evaluation in atrial fibrillation: results of the European Heart Rhythm Association survey

Torben Bjerregaard Larsen^*, Tatjana Potpara, Nikolaos Dagres, Laurent Pison, Heidi Estner, Carina Blomstrom-Lundqvist

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The aim of this European Heart Rhythm Association (EHRA) survey was to assess clinical practice in relation to stroke and bleeding risk evaluation in atrial fibrillation, particularly regarding the use of risk evaluation schemes, among members of the EHRA electrophysiology (EP) research network. In this EP Wire survey, we have provided some insights into current practice in Europe for the use of these risk assessment schemes. There were some obvious practice differences. However, reassuring information on current practice in Europe was evident, but more focus on renal function is warranted, especially facing the fact that novel oral anticoagulants are used for antithrombotic therapy.

Original language	English
Pages (from-to)	698-702
Journal	EP Europace
Volume	16
Issue number	5
DOIs	https://doi.org/10.1093/europace/euu089
Publication status	Published - May 2014

Keywords

Atrial fibrillation
Anticoagulation
Stroke
Bleeding
Risk stratification
CHADS(2)
CHA(2)DS(2)-VASc
HAS-BLED
New oral anticoagulants
Warfarin
EHRA survey
EP wire
Guidelines

Access to Document

10.1093/europace/euu089

Cite this

@article{9a6a7413d7b04c759a64b94d175d19db,

title = "Stroke and bleeding risk evaluation in atrial fibrillation: results of the European Heart Rhythm Association survey",

abstract = "The aim of this European Heart Rhythm Association (EHRA) survey was to assess clinical practice in relation to stroke and bleeding risk evaluation in atrial fibrillation, particularly regarding the use of risk evaluation schemes, among members of the EHRA electrophysiology (EP) research network. In this EP Wire survey, we have provided some insights into current practice in Europe for the use of these risk assessment schemes. There were some obvious practice differences. However, reassuring information on current practice in Europe was evident, but more focus on renal function is warranted, especially facing the fact that novel oral anticoagulants are used for antithrombotic therapy.",

keywords = "Atrial fibrillation, Anticoagulation, Stroke, Bleeding, Risk stratification, CHADS(2), CHA(2)DS(2)-VASc, HAS-BLED, New oral anticoagulants, Warfarin, EHRA survey, EP wire, Guidelines",

author = "Larsen, {Torben Bjerregaard} and Tatjana Potpara and Nikolaos Dagres and Laurent Pison and Heidi Estner and Carina Blomstrom-Lundqvist",

year = "2014",

month = may,

doi = "10.1093/europace/euu089",

language = "English",

volume = "16",

pages = "698--702",

journal = "EP Europace",

issn = "1099-5129",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Stroke and bleeding risk evaluation in atrial fibrillation: results of the European Heart Rhythm Association survey

AU - Larsen, Torben Bjerregaard

AU - Potpara, Tatjana

AU - Dagres, Nikolaos

AU - Pison, Laurent

AU - Estner, Heidi

AU - Blomstrom-Lundqvist, Carina

PY - 2014/5

Y1 - 2014/5

N2 - The aim of this European Heart Rhythm Association (EHRA) survey was to assess clinical practice in relation to stroke and bleeding risk evaluation in atrial fibrillation, particularly regarding the use of risk evaluation schemes, among members of the EHRA electrophysiology (EP) research network. In this EP Wire survey, we have provided some insights into current practice in Europe for the use of these risk assessment schemes. There were some obvious practice differences. However, reassuring information on current practice in Europe was evident, but more focus on renal function is warranted, especially facing the fact that novel oral anticoagulants are used for antithrombotic therapy.

AB - The aim of this European Heart Rhythm Association (EHRA) survey was to assess clinical practice in relation to stroke and bleeding risk evaluation in atrial fibrillation, particularly regarding the use of risk evaluation schemes, among members of the EHRA electrophysiology (EP) research network. In this EP Wire survey, we have provided some insights into current practice in Europe for the use of these risk assessment schemes. There were some obvious practice differences. However, reassuring information on current practice in Europe was evident, but more focus on renal function is warranted, especially facing the fact that novel oral anticoagulants are used for antithrombotic therapy.

KW - Atrial fibrillation

KW - Anticoagulation

KW - Stroke

KW - Bleeding

KW - Risk stratification

KW - CHADS(2)

KW - CHA(2)DS(2)-VASc

KW - HAS-BLED

KW - New oral anticoagulants

KW - Warfarin

KW - EHRA survey

KW - EP wire

KW - Guidelines

U2 - 10.1093/europace/euu089

DO - 10.1093/europace/euu089

M3 - Article

C2 - 24798958

SN - 1099-5129

VL - 16

SP - 698

EP - 702

JO - EP Europace

JF - EP Europace

IS - 5

ER -

Stroke and bleeding risk evaluation in atrial fibrillation: results of the European Heart Rhythm Association survey

Abstract

Keywords

Access to Document

Fingerprint

Cite this